Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kay

Showing results (11-20 of 172) with videos related to

Pageof 18
Sort By:
Arthritis Research & Therapy|May 19, 2011
Biosimilars: a regulatory perspective from AmericaJonathan Kay
Current Opinion in Rheumatology|March 18, 2017
Biosimilars: implications for rheumatoid arthritis therapyStanley Cohen, Jonathan Kay
Annals of the Rheumatic Diseases|October 21, 2010
Gadolinium and systemic fibrosis: guilt by associationJonathan Kay, László Czirják
Nature Reviews. Rheumatology|August 19, 2015
Biosimilars in rheumatology: current perspectives and lessons learntThomas Dörner, Jonathan Kay
Rheumatic Diseases Clinics of North America|July 7, 2019
Controversies in RheumatologyJonathan Kay, Sergio Schwartzman
Annals of the Rheumatic Diseases|June 16, 2009
Methotrexate: the gold standard without standardisationJonathan Kay, Rene Westhovens
The Journal of Rheumatology|February 15, 2025
Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis CareShao-Hsien Liu, Jonathan Kay
Rheumatic Diseases Clinics of North America|October 1, 2019
The "Treat to Target" Approach to Rheumatoid ArthritisKaren Salomon-Escoto, Jonathan Kay
Nature Reviews. Rheumatology|June 6, 2012
The advent of biosimilar therapies in rheumatology--"O brave new world"Morton A Scheinberg, Jonathan Kay
Rheumatic Diseases Clinics of North America|November 25, 2010
Rheumatic manifestations of diabetes mellitusDorota Lebiedz-Odrobina, Jonathan Kay
Pageof 18

Showing results (11-20 of 172) with videos related to

Sort By:
Pageof 18
Arthritis Research & Therapy|May 19, 2011
Biosimilars: a regulatory perspective from AmericaJonathan Kay
Current Opinion in Rheumatology|March 18, 2017
Biosimilars: implications for rheumatoid arthritis therapyStanley Cohen, Jonathan Kay
Annals of the Rheumatic Diseases|October 21, 2010
Gadolinium and systemic fibrosis: guilt by associationJonathan Kay, László Czirják
Nature Reviews. Rheumatology|August 19, 2015
Biosimilars in rheumatology: current perspectives and lessons learntThomas Dörner, Jonathan Kay
Rheumatic Diseases Clinics of North America|July 7, 2019
Controversies in RheumatologyJonathan Kay, Sergio Schwartzman
Annals of the Rheumatic Diseases|June 16, 2009
Methotrexate: the gold standard without standardisationJonathan Kay, Rene Westhovens
The Journal of Rheumatology|February 15, 2025
Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis CareShao-Hsien Liu, Jonathan Kay
Rheumatic Diseases Clinics of North America|October 1, 2019
The "Treat to Target" Approach to Rheumatoid ArthritisKaren Salomon-Escoto, Jonathan Kay
Nature Reviews. Rheumatology|June 6, 2012
The advent of biosimilar therapies in rheumatology--"O brave new world"Morton A Scheinberg, Jonathan Kay
Rheumatic Diseases Clinics of North America|November 25, 2010
Rheumatic manifestations of diabetes mellitusDorota Lebiedz-Odrobina, Jonathan Kay
Pageof 18